Decreased viability was shown to be due to the induction of a G2/M cell cycle arrest via CHK1 phosphorylation, revealing TIMELESS as a potential target for colon cancer therapy, particularly in combination with other DNA damaging agents or CHK1/Wee1 inhibition [18]. Here, TIMELESS is linked to malignant colon neoplasm.